Health Salon

Your Source for Cutting Edge Information in Alternative Health Care thats hard to find.




  • Subscribe

    • AddThis Feed Button

Links

Iodine in Graves Disease, neonatal

17th September 2007 by Arrow Durfee Posted in Uncategorized

content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ProduktNr=224239&Ausgabe=225771&ArtikelNr=20989&filename=20989.pdf

Vol. 15, No. 2, 2000 Opens in a new window Medline Abstract (ID 10720879)

Free Abstract Article (References) Article (PDF 342 KB)

Paper

Efficacy of Oral Iodide Therapy on Neonatal Hyperthyroidism Caused by Maternal Graves’ Disease
A Case Report
G. Maraglianoa, A.A. Zuppaa, M.G. Florioa, M.E. Scapillatia, P. Girlandoa, B. Crescimbinia, C. Cafforioa, G. Noiab, A.F. Cavaliereb, G. Tortoroloa

aInstitute of Pediatrics, Department of Neonatology,
bInstitute of Obstetrics and Gynaecology, Catholic University of the Sacred Heart, Rome, Italy

Address of Corresponding Author

Fetal Diagnosis and Therapy 2000;15:122-126 (DOI: 10.1159/000020989)

goto top of page Key Words

Objective: To verify the efficacy of oral iodide therapy in treating a case of early neonatal hyperthyroidism due to maternal Graves’ disease. Methods: We report a case of neonatal hyperthyroidism which occurred in a 2,650-gram, female baby, born at 39 weeks’ gestational age (GA) to a 30-year-old mother affected by Graves’ disease and treated with thionamides (propylthiouracil) from the 20th week of gestation. A fetal goiter, due to maternal therapy, had been observed by ultrasound scan at 31 and 35 weeks of gestation, with contemporary low cord thyroid hormone levels. Two intra-amniotic injections of levothyroxine were then performed at 34 and 36 weeks of gestation, which led to a significant reduction of fetal goiter and to normalization of cord thyroid hormone levels.

The neonatal clinical course was characterized by symptoms of hyperthyroidism from the 2nd to 3rd days of life (irritability, tachycardia, tachypnea, hyperphagia), mostly during feeding. Oral treatment with potassium iodide (KI, 8 mg Å~ 3 times a day) was started at 23 days of life.

Results: Treatment with KI led to a significant reduction of neonatal clinical symptoms and to a normalization of hormone levels within 4 days of therapy. The treatment was discontinued in 13th week of life because of neonatal well-being and normal hormone levels. Conclusions: We believe that KI therapy is effective in treating neonatal hyperthyroidism and does not cause suppression of neonatal thyroid activity, which is possible using antithyroid drugs like thionamides.

Copyright © 2000 S. Karger AG, Basel

goto top of page Author Contacts

Giovanna Maragliano
Viale C. Pavese n. 260
I-00144 Rome (Italy)
Tel. +39 06 5015937, Fax +39 06 77055413

goto top of page Article Information

Received: Received: April 13, 1999
Accepted after revision: November 2, 1999
Number of Print Pages : 5
Number of Figures : 4, Number of Tables : 0, Number of References : 22

Free Abstract Article (References) Article (PDF 342 KB)

copyright © 2006 S. Karger AG, Basel

Related Posts:

Comments are closed.